[How to finance chemotherapy with new cancer drugs?
Recently developed drugs are ten to one hundred fold more costly than the chemotherapies of the past while the number of eligible patients and the average duration of treatments are ever increasing. The combined effect of these trends makes budgeting a daunting task, in particular for hospitals with budgetary allocation. Balancing budgets became difficult with the arrival of taxanes, but innovative therapies based on biotechnological advances will further increase the financial slide. Hospital running costs can not be infinitely reduced. Therefore, new rules that govern the financing of innovative therapies become mandatory and budgetary allocations based on DRG evaluations will no longer be feasible.
Livartowski
A
A
Institut Curie, 26, rue d'Ulm, 75248 Paris Cedex 05.
Beuzeboc
P
P
Le Vu
B
B
Courbard
M
M
Pierga
J Y
JY
Extra
J M
JM
Scholl
S
S
Pouillart
P
P
D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000191:economics; D002017:Budgets / Q000379:methods*; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000191:economics; D003953:Diagnosis-Related Groups / Q000191:economics*; D016527:Drug Costs / Q000639:trends; D005260:Female; D005544:Forecasting; D005602:France; D017408:Guidelines as Topic; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000191:economics; D009369:Neoplasms / Q000188:drug therapy / Q000191:economics*
D000970:Antineoplastic Agents